Advanced heart failure therapy has been revolutionized with the advent of continuous-flow ventricular assist devices (CF-LVADs) which have improved both survival and quality of life. Despite this, support with CF-LVADs is frequently complicated, with 70% of recipients experiencing a major complication in the first year of durable support. The most concerning of these complications to emerge is device-related thrombosis, which is associated with increased morbidity and mortality. Pathophysiology and diagnosis are multifaceted and complex, with pump-specific and patient-specific factors to be considered. Incidence estimates are evolving with increases seen in the past 2 years compared with earlier implant data. Evidence for treatment is limited to case series and reports, which are subject to significant publication bias. Finally, appropriate primary and secondary prophylaxis is imprecise with multiple antiplatelet and antithrombotic strategies described. This review seeks to summarize the current literature surrounding the pathophysiology, diagnosis, and management of thrombosis in CF-LVAD recipients.
KirklinJKNaftelDCKormosRL. Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) analysis of pump thrombosis in the HeartMate II left ventricular assist device. J Heart Lung Transplant. 2014;33(1):12–22.
5.
GoldsteinDJJohnRSalernoC. Algorithm for the diagnosis and management of suspected pump thrombus. J Heart Lung Transplant. 2013;32(7):667–670.
6.
FrazierOHDelgadonRMKarB. First clinical use of the redesigned HeartMate® II left ventricular assist system in the United States. Tex Heart Inst J. 2004;31(2):157–159.
7.
StarlingRCMoazamiNSilvestrySC. Unexpected abrupt increase in left ventricular assist device thrombosis. N Engl J Med. 2014;370(1):33–40.
8.
UrielNHanJMorrisonKA. Device thrombosis in HeartMate II continuous-flow left ventricular assist devices: a multifactorial phenomenon. J Heart Lung Transplant. 2014;33(1):51–59.
9.
JohnRPanchSHrabeJ. Activation of endothelial and coagulation systems in left ventricular assist device recipients. Ann Thorac Surg. 2009;88(4):1171–1179.
10.
SlaughterMSSobieskiMA. Fibrinolytic activation during long-term support with the HeartMate II left ventricular assist device. ASAIO J. 2008;54(1):115–119.
11.
SlaughterMSSobieskiMAIIGrahamJD. Platelet activation in heart failure patients supported by the HeartMate II ventricular assist device. Int J Artif Organs. 2011;34(6):461–468.
12.
LitzlerPYSmailHBarbayV. Is anti-platelet therapy needed in continuous flow left ventricular assist device patients? A single-centre experience. Eur J Cardiothorac Surg. 2014;45(1):55–59.
13.
NajjarSSSlaughterMSPaganiFD. An analysis of pump thrombus events in patients in the HeartWare ADVANCE bridge to transplant and continued access protocol trial. J Heart Lung Transplant. 2014;33(1):23–34.
14.
TeutebergJJSlaughterMSRogersJ. Impact of device design and patient management on the incidence of neurologic events after HVAD left ventricular assist device. J Heart Lung Transplant. 2014;33(4):s10.
15.
BoyleAJRussellSDTeutebergJJ. Low thromboembolism and pump thrombosis with the HeartMate II left ventricular assist device: analysis of outpatient anti-coagulation. J Heart Lung Transplant. 2009;28(9):881–887.
16.
SlaughterMSPaganiFDRogersJG. Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. J Heart Lung Transplant. 2010;29(9):s1–s39.
17.
SundareswaranKSFarrarDJ. No difference in pump thrombosis in Heartmate II patients with gelatin sealed and unsealed vascular grafts. J Heart Lung Transplant. 2014;33(4):s131.
18.
ShahPMehtaVMCowgerJA. Diagnosis of hemolysis and device thrombosis with lactate dehydrogenase during left ventricular assist device support. J Heart Lung Transplant. 2014;33(1):102–104.
19.
RavichandranAKParkerJNovakE. Hemolysis in left ventricular assist devices: a retrospective analysis of outcomes. J Heart Lung Transplant. 2014;33(1):44–50.
MeyerALKuehnCWeidemannJ. Thrombus formation in a HeartMate II left ventricular assist device. J Thorac Cardiovasc Surg. 2008;135(1):203–204.
22.
UrielNMorrisonKAGaranAR. Development of a novel echocardiography ramp test for speed optimization and diagnosis of device thrombosis in continuous-flow left ventricular assist devices: the Columbia ramp study. J Am Coll Cardiol. 2012;60(18):1764–1775.
23.
GormanRGordanLZumbergM. Successful use of argatroban as an anticoagulant in burn-related severe acquired antithrombin III deficiency after heparin failure. Thromb Haemost. 2001;86(6):1596–1597.
24.
BadiyeAHernandezGAChaparroS. Argatroban as novel therapy for suspected thrombosis in patients with continuous flow left ventricle assist device and hemolysis. ASAIO J. 2014;60(3):361–365.
25.
ThomasMDWoodCLovettM. Successful treatment of rotary pump thrombus with the glycoprotein IIb/IIIa inhibitor tirofiban. J Heart Lung Transplant. 2008;27(8):925–927.
26.
BlaisDMSunBVescoP. Profound thrombocytopenia with glycoprotein IIb/IIIa inhibitors plus heparin for pump thrombus. J Heart Lung Transplant. 2008;27(12):1361–1362.
27.
Al-QuthamiAHJumeanMKociolR. Eptifibatide for the treatment of HeartMate II left ventricular assist device thrombosis. Circ Heart Fail. 2012;5(4):e68–e70.
28.
JenningsDLCabreraRWangDD. Successful treatment of a continuous flow left ventricular assist device thrombosis with eptifibatide. ASAIOJ. 2012;58(6):633–635.
29.
BellumkondaLSubrahmanyanLJacobyD. Left ventricular assist device pump thrombosis: is there a role for glycoprotein IIb/IIIa inhibitors?ASAIO J. 2014;60(1):134–136.
30.
TellorBRSmithJRPrasadSM. The use of eptifibatide for suspected pump thrombus or thrombosis in patients with left ventricular assist devices. J Heart Lung Transplant. 2014;33(1):94–101.
31.
RothenburgerMWilhelmMJHammelD. Treatment of thrombus formation associated with the MicroMed DeBakey VAD using recombinant tissue plasminogen activator. Circulation. 2002;106(suppl):I–189–I–192.
32.
DelgadoRFrazierOHMyersTJ. Direct thrombolytic therapy for intraventricular thrombosis in patients with the Jarvik 2000 left ventricular assist device. J Heart Lung Transplant. 2005;24(2):231–233.
33.
HayesHDemboLLarbalestierR. Successful treatment of ventricular assist device associated ventricular thrombus with systemic tenecteplase. Heart Lung Circ. 2008;17(3):253–255.
34.
KiernanMSPhamDTDenofrioD. Management of HeartWare left ventricular assist device thrombosis using intracavitary thrombolytics. J Thorac Cardiovasc Surg. 2011;142(3):712–714.
35.
ThenappanTAndersonASJeevanadhamV. Treatment of left ventricular assist device thrombosis with extended catheter-directed intraventricular thrombolytic therapy. Circ Heart Fail. 2013;6(3):e27–e29.
MuthiahKMacdonaldPSKotlyarE. Thrombolysis for suspected intrapump thrombosis in patients with continuous flow centrifugal left ventricular assist device. Artif Organs. 2013;37(3):313–322.
38.
AissaouiNBorgermannJGummertJ. HeartWare continuous-flow ventricular assist device thrombosis: the Bad Oeynhausen experience. J Thorac Cardiovasc Surg. 2012;143(4):e37–e39.
39.
KamouhAJohnREckmanP. Successful treatment of early thrombosis of HeartWare left ventricular assist device with thrombolytics. Ann Thorac Surg. 2012;94(1):281–283.
40.
JabbarAAYauRFrazierOH. Direct thrombolytic therapy for thrombosis of a centrifugal flow left ventricular assist device. ASAIO J. 2013;59(5):530–532.
41.
DalenMSartipyUCorbascioM. HeartWare left ventricular assist device thrombosis in aspirin non-responder. Asian Cardiovasc Thorac Ann. 2014;22(2):203–204.
42.
SantiseGSciaccaSBagliniR. Can learning to interpret pump messages help lead to an early diagnosis of HeartWare ventricular assist device thrombosis?ASAIO J. 2012;58(6):629–632.
43.
EckmanPMJohnR. Bleeding and thrombosis in patients with continuous-flow ventricular assist devices. Circulation. 2012;125(24):3038–3047.
44.
GregoricIDBrucknerBAJacobL. Clinical experience with sternotomy versus subcostal approach for exchange of the HeartMate XVE to the HeartMate II ventricular assist device. Ann Thorac Surg. 2008;85(5):1646–1649.
45.
BirschmannIDittrichMEllerT. Ambient hemolysis and activation of coagulation is different between HeartMate II and HeartWare left ventricular assist devices. J Heart Lung Transplant. 2014;33(1):80–87.
46.
SandnerSERiebandtJHaberlT. Low-molecular-weight heparin for anti-coagulation after left ventricular assist device implantation. J Heart Lung Transplant. 2014;33(1):88–93.
47.
FeldmanDPamboukianSVTeutebergJJ. The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary. J Heart Lung Transplant. 2013;32(2):157–187.
48.
SlaughterMSPaganiFDMcGeeEC. HeartWare ventricular assist system for bridge to transplant: combined results of the bridge to transplant and continued access protocol trial. J Heart Lung Transplant. 2013;32(7):675–683.
